QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=1EDBFD0B90CFBDE8728FB2012F93D54F;jsessionid=7C5F5322CA1C18B24FF484074A895AB9;jsessionid=091E8B2120A92BEE2EE553A012936A65;jsessionid=6A1DB25910FB98F5D60C534D6E9A5491;jsessionid=304444EF5381EC90FC0548576732CA12;jsessionid=DCAC5DDEE1429C35D530671F333574F7;jsessionid=BB04E5800CFE9193EC768B5CEB94979F (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=1EDBFD0B90CFBDE8728FB2012F93D54F;jsessionid=7C5F5322CA1C18B24FF484074A895AB9;jsessionid=091E8B2120A92BEE2EE553A012936A65;jsessionid=6A1DB25910FB98F5D60C534D6E9A5491;jsessionid=304444EF5381EC90FC0548576732CA12;jsessionid=DCAC5DDEE1429C35D530671F333574F7;jsessionid=BB04E5800CFE9193EC768B5CEB94979F